Format

Send to

Choose Destination
Pediatr Blood Cancer. 2012 Aug;59(2):365-71. doi: 10.1002/pbc.24178. Epub 2012 Apr 19.

Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.

Author information

1
Division of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. jstrous1@jhmi.edu

Abstract

Hydroxyurea is the only approved medication in the United States for the treatment of sickle cell anemia (HbSS) and is widely used in children despite an indication limited to adults. We review the evidence of efficacy and safety in children with reference to pivotal adult studies. This evidence and expert opinion form the basis for recommended guidelines for the use of hydroxyurea in children including indications, dosing, therapeutic and safety monitoring, and interventions to improve adherence. However, there are substantial gaps in our knowledge to be addressed by on-going and planned studies in children.

PMID:
22517797
PMCID:
PMC3374046
DOI:
10.1002/pbc.24178
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center